Company Description
Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada.
It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products.
The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer.
It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products.
In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications.
Sunshine Biopharma, Inc. is based in Fort Lauderdale, Florida.
| Country | United States |
| Founded | 2006 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 44 |
| CEO | Steve Slilaty |
Contact Details
Address: 333 Las Olas Way, CU4 Suite 433 Fort Lauderdale, Florida 33301 United States | |
| Phone | 954-515-0810 |
| Website | sunshinebiopharma.com |
Stock Details
| Ticker Symbol | SBFM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001402328 |
| CUSIP Number | 867781304 |
| ISIN Number | US8677814035 |
| Employer ID | 20-5566275 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Steve N. Slilaty Ph.D. | Chairman, President and Chief Executive Officer |
| Camille Sebaaly | Chief Financial Officer and Secretary |
| Dr. Abderrazzak Merzouki | Chief Science Officer and Director |
| Malek Chamoun | Chief Development Officer |
| Robert G. Ferreira | President of Sunshine Bio Investments Inc |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 10, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 424B4 | Prospectus |
| Nov 8, 2024 | EFFECT | Notice of Effectiveness |
| Nov 7, 2024 | 8-K | Current Report |
| Nov 6, 2024 | POS AM | Post-Effective amendments for registration statement |
| Nov 5, 2024 | 10-Q | Quarterly Report |
| Oct 23, 2024 | 8-K | Current Report |
| Oct 17, 2024 | DEF 14A | Other definitive proxy statements |
| Sep 10, 2024 | 8-K | Current Report |